Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · September 25, 2022

Sacubitril/Valsartan and Frailty in Patients With HFpEF

Journal of the American College of Cardiology

 

Additional Info

Journal of the American College of Cardiology
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
J Am Coll Cardiol 2022 Sep 20;80(12)1130-1143, JH Butt, P Dewan, PS Jhund, IS Anand, D Atar, J Ge, AS Desai, LE Echeverria, L Køber, CSP Lam, AP Maggioni, F Martinez, M Packer, JL Rouleau, D Sim, DJ Van Veldhuisen, B Vrtovec, F Zannad, MR Zile, J Gong, MP Lefkowitz, AR Rizkala, SD Solomon, JJV McMurray

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading